Enzon to Review Potential Sale After Icahn Says He Wants Talk

Monday, 17 Dec 2012 08:31 AM

 

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink

Enzon Pharmaceuticals Inc., a developer of cancer treatments, said it is considering selling all or part of the business after billionaire investor Carl Icahn expressed interest in talking to the company.

Lazard Ltd. was hired to help explore the possibility of a sale, Piscataway, New Jersey-based Enzon said Monday in a statement. To conserve cash, Enzon suspended development and testing of its androgen receptor treatment.

Icahn said Nov. 28 he had informed the company that he wanted to discuss its operations, direction and plans to manage expenses, according to a regulatory filing. Icahn’s firm owned 13.3 percent of Enzon shares as of Nov. 9. Enzon has a treatment for breast and colorectal cancer in the second of three stages of development typically needed to get regulatory approval.

“Enzon’s drug candidates and technologies offer the potential for a variety of transactions,” Alex Denner, chairman of Enzon’s board, said in the statement.

Enzon shares have fallen 32 percent this year, giving the company a market value of $203 million.

© Copyright 2014 Bloomberg News. All rights reserved.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web

Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 

You May Also Like
Around the Web

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved